Beta Drugs share news and announcements
Last close ₹1,894.60down ₹76.40 (3.88%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,971.00.
52-week range of traded prices to 23 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,107 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 22 Oct 2026
- 39.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 Oct 2026
- 4.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 22 Oct 2026
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 22 Oct 2026
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 22 Oct 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,55,58635.7% delivered
Beta Drugs board meetings
112 filed, newest first. Page 1 of 3.
Oct 2026
Sep 2026
3 Sep · Board meeting
Aug 2026
31 Aug · Board meeting
18 Aug · Board meeting
Jul 2026
May 2026
25 May · Board meeting
Apr 2026
25 Apr · Board meeting
Feb 2026
Jan 2026
9 Jan · Board meeting
Nov 2025
29 Nov · Board meeting
Sep 2025
3 Sep · Board meeting
May 2025
Mar 2025
Feb 2025
5 Feb · Board meeting
Nov 2024
27 Nov · Board meeting
Oct 2024
19 Oct · Board meeting
19 Oct · Board meeting
16 Oct · Board meeting
Aug 2024
31 Aug · Board meeting
Jul 2024
8 Jul · Board meeting
May 2024
Nov 2023
7 Nov · Board meeting
7 Nov · Board meeting
Oct 2023
Sep 2023
1 Sep · Board meeting
Apr 2023
Oct 2022
Aug 2022
Jul 2022
Jun 2022
Apr 2022
Jan 2022
20 Jan · Board meeting
Oct 2021
25 Oct · Board meeting
25 Oct · Board meeting
Aug 2021
31 Aug · Board meeting
31 Aug · Board meeting
26 Aug · Board meeting
Apr 2021
27 Apr · Board meeting